143 related articles for article (PubMed ID: 2102478)
21. [The efficacy of bone scintigraphy screening in postoperative follow-up of breast cancer patients].
Ohnari N; Shiozaki H; Ishino Y; Nakata H
Gan No Rinsho; 1990 Dec; 36(15):2546-8. PubMed ID: 2266587
[TBL] [Abstract][Full Text] [Related]
22. Changes in parameters of bone and mineral metabolism during therapy for hyperthyroidism.
Pantazi H; Papapetrou PD
J Clin Endocrinol Metab; 2000 Mar; 85(3):1099-106. PubMed ID: 10720046
[TBL] [Abstract][Full Text] [Related]
23. [Bone scintigraphy for the staging of lymphogranulomatosis?].
Hundeshagen H; Diehl V; Creutzig H
Strahlentherapie; 1985 Aug; 161(8):502-5. PubMed ID: 4024169
[TBL] [Abstract][Full Text] [Related]
24. The use of bone markers in a 6-week study to assess the efficacy of oral clodronate in patients with metastatic bone disease.
Brown JE; McCloskey EV; Dewar JA; Body JJ; Cameron DA; Harnett AN; Ruutu M; Purohit OP; Tähtelä R; Coleman RE
Calcif Tissue Int; 2007 Nov; 81(5):341-51. PubMed ID: 17874331
[TBL] [Abstract][Full Text] [Related]
25. [Clinicopathological study of gastric cancer with bone metastasis].
Nishidoi H; Koga S
Gan To Kagaku Ryoho; 1987 May; 14(5 Pt 2):1717-22. PubMed ID: 3592711
[TBL] [Abstract][Full Text] [Related]
26. The value of combination of bone scanning and measurement of carcinoembryonic antigen in diagnosis of breast cancer metastases.
Kausitz J; Makaiová I; Hupka S; Vivodová M
Czech Med; 1981; 4(3):159-62. PubMed ID: 7307849
[TBL] [Abstract][Full Text] [Related]
27. Effects of gonadal steroid suppression on skeletal sensitivity to parathyroid hormone in men.
Leder BZ; Smith MR; Fallon MA; Lee ML; Finkelstein JS
J Clin Endocrinol Metab; 2001 Feb; 86(2):511-6. PubMed ID: 11158001
[TBL] [Abstract][Full Text] [Related]
28. [Prevalence of elevated serum CA 15-3 at time of metastatic relapse of breast cancer and correlation with hormone receptor status].
Bensouda Y; André F; Boulet T; Al-Ghuzlan A; Conforti R; Troalen F; Bourgier C; Errihani H; Spielmann M; Delaloge S
Bull Cancer; 2009 Oct; 96(10):923-8. PubMed ID: 19696005
[TBL] [Abstract][Full Text] [Related]
29. [Evaluation of two serum isoenzyme phosphatases as bone metastasis markers].
Desoize B; Pourny C; Amico S; Larbre H; Jardillier JC
Bull Cancer; 1990; 77(12):1211-21. PubMed ID: 2081281
[TBL] [Abstract][Full Text] [Related]
30. [The tumor markers CEA, TPA and CA 19-9 and ferritin and osteocalcin in follow-up studies in breast cancer].
Schatz C; von Lieven H; Mulders M; Rowold J; Stracke H; Müller H; Grebe SF; Schatz H
Wien Klin Wochenschr; 1985 Dec; 97(23):873-9. PubMed ID: 3878042
[TBL] [Abstract][Full Text] [Related]
31. Serum osteocalcin measurements in prostate carcinoma patients with skeletal deposits shown by bone scintigram: comparison with serum PSA/PAP measurements.
Shih WJ; Wierzbinski B; Collins J; Magoun S; Chen IW; Ryo UY
J Nucl Med; 1990 Sep; 31(9):1486-9. PubMed ID: 1697617
[TBL] [Abstract][Full Text] [Related]
32. Biochemical picture of bone metabolism in breast cancer patients with bone metastases.
Berruti A; Torta M; Piovesan A; Raucci CA; Orlandi F; Panero A; Dogliotti L; Angeli A
Anticancer Res; 1995; 15(6B):2871-5. PubMed ID: 8669881
[TBL] [Abstract][Full Text] [Related]
33. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis.
Koizumi M; Takahashi S; Ogata E
Anticancer Res; 2003; 23(5b):4095-9. PubMed ID: 14666607
[TBL] [Abstract][Full Text] [Related]
34. Determination and biological relevance of serum cross-linked type I collagen N-telopeptide and bone-specific alkaline phosphatase in breast metastatic cancer.
Kanakis I; Nikolaou M; Pectasides D; Kiamouris C; Karamanos NK
J Pharm Biomed Anal; 2004 Mar; 34(4):827-32. PubMed ID: 15019061
[TBL] [Abstract][Full Text] [Related]
35. Single determination of CA 15.3 and bone scintigraphy in the diagnosis of skeletal metastases of breast cancer.
Crippa F; Bombardieri E; Seregni E; Castellani MR; Gasparini M; Maffioli L; Pizzichetta M; Buraggi GL
J Nucl Biol Med (1991); 1992; 36(1):52-5. PubMed ID: 1450226
[TBL] [Abstract][Full Text] [Related]
36. [Osteocalcin, a marker in diseases with elevated bone metabolism].
Stracke H; Schatz C; Pralle H; Ullmann J; Schatz H
Dtsch Med Wochenschr; 1985 Sep; 110(38):1442-6. PubMed ID: 3875469
[TBL] [Abstract][Full Text] [Related]
37. [Evaluation of cancer-induced bone diseases by bone metabolic marker].
Takahashi S
Clin Calcium; 2006 Apr; 16(4):581- 90. PubMed ID: 16582508
[TBL] [Abstract][Full Text] [Related]
38. Clinical and imaging correlations of bone turnover markers in prostate cancer patients with bone only metastases.
Zafeirakis AG; Papatheodorou GA; Limouris GS
Nucl Med Commun; 2010 Mar; 31(3):249-53. PubMed ID: 20038858
[TBL] [Abstract][Full Text] [Related]
39. [Bone imaging in the detection of skeletal metastasis].
Shi QX
Zhonghua Zhong Liu Za Zhi; 1989 May; 11(3):196-8. PubMed ID: 2612332
[TBL] [Abstract][Full Text] [Related]
40. Bone turnover markers and bone scintigraphy in the evaluation of the skeletal metastases.
Chrapko BE; Nocuń A; Gołebiewska R; Jankowska H; Zaorska-Rajca J
Nucl Med Rev Cent East Eur; 2005; 8(2):100-4. PubMed ID: 16437394
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
